TherapeuticsMD, Inc. (TXMD) has been given an average price target of $22.17 from analysts, according to data collected by Finviz. Analyst's mean target price for CHK is $7.31 while analysts mean recommendation is 2.80. The average 12-month price objective among analysts that have updated their coverage on the stock in the past year is $19.40.
(NYSEMKT:TXMD)'s Buy count is 0 and Strong Buy is 6 while the number of analysts recommending Sell and Strong Sell are 0 and 0, respectively. Zacks Investment Research upgraded TherapeuticsMD from a "sell" rating to a "hold" rating in a report on Tuesday, January 24th. Cantor Fitzgerald restated an "overweight" rating and set a $34.00 price target on shares of TherapeuticsMD in a report on Monday, March 6th.
TherapeuticsMD, Inc. had its " rating reiterated by analysts at Stifel Nicolaus.
TherapeuticsMD (NYSEMKT:TXMD) opened at 5.51 on Wednesday. The business earned $4.49 million during the quarter, compared to the consensus estimate of $5.91 million. The total market capitalization remained at $225.25 billion.
Stock is now moving with a negative distance from the 200 day simple moving average of approximately -23.72%, and has a poor year to date (YTD) performance of -13.17% which means the stock is constantly subtracting to its value from the previous fiscal year end price. (TXMD) now has a value of $4.85 while the company's 52 week low is at $4.39, the shares dropped to the 52 week low on 11/04/16. The stock lost -6.53% in total of its share price. The high and low revenue estimates for the current quarter are $5.86 Million and $4.53 Million, respectively. The company reported revenue of $0 in the same period past year. Equities research analysts predict that TherapeuticsMD will post ($0.42) EPS for the current fiscal year. A month ago, analyst EPS consensus estimated earnings of US$-0.12 per share.
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. raised its position in shares of TherapeuticsMD by 20.3% in the fourth quarter. There is no concrete way to calculate a price target. BlackRock Fund Advisors boosted its position in TherapeuticsMD by 9.2% in the third quarter.
The company declined -5.83% and closed its last trading session at $5.15. Traynor Capital Management Inc. raised its position in TherapeuticsMD by 21.2% in the third quarter. BlackRock Investment Management LLC now owns 569,885 shares of the specialty pharmaceutical company's stock valued at $3,881,000 after buying an additional 7,579 shares during the last quarter. State Street Corp boosted its position in TherapeuticsMD by 9.1% in the fourth quarter.
07/08/2014 - FBR Capital Markets began new coverage on TherapeuticsMD, Inc. giving the company a "outperform" rating.
06/17/2014 - JMP Securities began new coverage on TherapeuticsMD, Inc. giving the company a "outperform" rating. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company's late stage clinical pipeline includes two phase 3 product candidates: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.